As demand for life-saving nucleic acid therapeutics surges, there is a push in the industry to actively transition from legacy phosphoramidite chemistry to more sustainable manufacturing paradigms. Traditional solid-phase oligonucleotide synthesis (SPOS) relies on large volumes of hazardous organic solvents (like acetonitrile and dichloromethane) and generates significant chemical waste. To mitigate these environmental and operational burdens, researchers and Contract Development and Manufacturing Organizations (CDMOs) are exploring greener pathways, such as continuous liquid-phase processing and template-independent enzymatic synthesis (EOS) using engineered enzymes in benign, water-based buffers. While solid-phase methods remain the current reference standard, this shift toward eco-conscious approaches promises to reduce toxicity, minimize cost, and drastically increase scalability for modern blockbuster drugs.  Or does it?